본문 바로가기
KERD
논문KCI 등재

Tumor Therapy Applying Membrane-bound Form of Cytokines

김영상
대한면역학회 (The Korean Association of Immunologists)|2009.11|Immune Network|제9권 제5호|pp. 158-168

2

조회

0

다운로드

4

인용

0

참고문헌

키워드

CTLtumor therapymembrane-bound form of cytokine

초록

Tumor therapy using cytokines has been developed for last two decades. Several recombinant cytokines and tumor cell vaccines produced by cytokine gene transfer have been in clinical trials, but several side effects hamper routine clinical applications. Many cytokines are originally expressed as membrane-bound form and then processed to secretory form exerting paracrine effects. Though functional differences of these two types of cytokines are elusive yet, the membrane-bound form of cytokine may exert its effects on restricted target cells as a juxtacrine, which are in physical contacts. With the efforts to improve antitumor activities of cytokines in cancer patients, developing new strategies to alleviate life-threatening side effects became an inevitable goal of tumor immunologists. Among these, tumor cell vaccines expressing cytokines as membrane-bound form on tumor cell surface have been developed by genetic engineering techniques with the hope of selective stimulation of the target cells that are in cell-to-cell contacts. In this review, recent progress of tumor cell vaccines expressing membrane-bound form of cytokines will be discussed.

Abstract

Tumor therapy using cytokines has been developed for last two decades. Several recombinant cytokines and tumor cell vaccines produced by cytokine gene transfer have been in clinical trials, but several side effects hamper routine clinical applications. Many cytokines are originally expressed as membrane-bound form and then processed to secretory form exerting paracrine effects. Though functional differences of these two types of cytokines are elusive yet, the membrane-bound form of cytokine may exert its effects on restricted target cells as a juxtacrine, which are in physical contacts. With the efforts to improve antitumor activities of cytokines in cancer patients, developing new strategies to alleviate life-threatening side effects became an inevitable goal of tumor immunologists. Among these, tumor cell vaccines expressing cytokines as membrane-bound form on tumor cell surface have been developed by genetic engineering techniques with the hope of selective stimulation of the target cells that are in cell-to-cell contacts. In this review, recent progress of tumor cell vaccines expressing membrane-bound form of cytokines will be discussed.

참고문헌 (94)

  1. Tepper RI, "Experimental and clinical studies of cytokine gene-modified tumor cells", Hum Gene Ther, 5, pp.153~164 (1994)
  2. Blankenstein T, "Cytokines and cancer: experimental systems", Curr Opin Immunol, 3, pp.694~698 (1991)
  3. Colombo MP, "Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?", Immunol Today, 15, pp.48~51 (1994)
  4. Dranoff G, "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity", Proc Natl Acad Sci U S A, 90, pp.3539~3543 (1993)
  5. Zier K, "Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy", Immunol Today, 17, pp.39~45 (1996)
  6. Gabrilovich DI, "Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts", Cell Immunol, 170, pp.101~110 (1996)
  7. Kurt-Jones EA, "Membrane interleukin 1 induction on human endothelial cells and dermal fibroblasts", J Immunol, 139, pp.2317~2324 (1987)
  8. Musso T, "Human monocytes constitutively express membranebound,biologically active, and interferon-gamma-upregulated interleukin-15", Blood, 93, pp.3531~3539 (1999)
  9. Cerretti DP, "Human macrophage-colony stimulating factor: alternative RNA and protein processing from a single gene", Mol Immunol, 25, pp.761~770 (1988)
  10. Lyman SD, "Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs", Oncogene, 10, pp.149~157 (1995)
  11. Kriegler M, "A novel form of TNF", cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF, 1988, pp.53, 45~53
  12. Browning JL, "Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface", Cell, 72, pp.847~856 (1993)
  13. Bazan JF, "A new class of membrane-bound chemokine with a CX3C motif", Nature, 385, pp.640~644 (1997)
  14. Nakamura K, "Cell contact-dependent immunosuppression by CD4(＋)CD25(＋) regulatory T cells is mediated by cell surface-bound transforming growth factor beta", J Exp Med, 194, pp.629~644 (2001)
  15. Assenmacher M, "Specific expression of surface interferon-gamma on interferon-gamma producing T cells from mouse and man", Eur J Immunol, 26, pp.263~267 (1996)
  16. Carswell EA, "An endotoxin-induced serum factor that causes necrosis of tumors", Proc Natl Acad Sci U S A, 72, pp.3666~3670 (1975)
  17. Li X, "Loss of ectodomain shedding due to mutations in the metalloprotease and cysteine-rich", disintegrin domains of the tumor necrosis factor-alpha converting enzyme (TACE), 2004, pp.279, 27365~27375
  18. Black RA, "Tumor necrosis factor-alpha converting enzyme", Int J Biochem Cell Biol, 34, pp.1~5 (2002)
  19. Mueller DL, "Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy", Annu Rev Immunol, 7, pp.445~480 (1989)
  20. Aversa G, "The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4＋ T cell clones provides a costimulatory signal for human B cell activation", J Exp Med, 177, pp.1575~1585 (1993)
  21. Birkland TP, "Soluble TNF and membrane TNF expressed on CD4＋ T lymphocytes differ in their ability to activate macrophage antiLeishmanial defense", J Leukoc Biol, 51, pp.296~299 (1992)
  22. Mueller C, "Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo", J Biol Chem, 274, pp.38112~38118 (1999)
  23. Fichtner I, "Determination of antineoplastic activity and toxicity of tumor necrosis factor (TNF) in animal experiments in Correlation to clinical findings", Neoplasma, 37, pp.301~315 (1990)
  24. Tracey KJ, "Tumor necrosis factor: a pleiotropic cytokine and therapeutic target", Annu Rev Med, 45, pp.491~503 (1994)
  25. Marr RA, "Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha", Gene Ther, 4, pp.1181~1188 (1997)
  26. Li Q, "Mechanism of action differences in the antitumor effects of transmembrane and secretory tumor necrosis factor-alpha in vitro and in vivo", Cancer Immunol Immunother, 55, pp.1470~1479 (2006)
  27. Rieger R, "Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity", Cancer Gene Ther, 16, pp.53~64 (2009)
  28. Burgess AW, "Purification and properties of colony-stimulating factor from mouse lung-conditioned medium", J Biol Chem, 252, pp.1998~2003 (1977)
  29. Pluznik DH, "The induction of clones of normal mast cells by a substance from conditioned medium", Exp Cell Res, 43, pp.553~563 (1966)
  30. Witmer-Pack MD, "Granulocyte", macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells, 1987, pp.166, 1484~1498
  31. Mach N, "Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand", Cancer Res, 60, pp.3239~3246 (2000)
  32. Soo Hoo W, "Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model", J Immunol, 162, pp.7343~4349 (1999)
  33. Yei S, "Novel membranebound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 mela noma cell vaccine", Gene Ther, 9, pp.1302~1311 (2002)
  34. el-Shami KM, "Induction of antitumor immunity with modified autologous cells expressing membrane-bound murine cytokines", J Interferon Cytokine Res, 19, pp.1391~1401 (1999)
  35. Ling X, "Vaccination with leukemia cells expressing cell-surface- associated GM-CSF blocks leukemia induction in immunocompetent mice", Oncogene, 25, pp.4483~4490 (2006)
  36. Douglass TG, "Macrophage colony stimulating factor: not just for macrophages anymore! A gateway into complex biologies", Int Immunopharmacol, 8, pp.1354~1376 (2008)
  37. Rosenberg SA, "Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer", J Natl Cancer Inst, 85, pp.622~632 (1993)
  38. Fisher RI, "Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma", Cancer J Sci Am 6 Suppl, 1, pp.55~57 (2000)
  39. Assier E, "NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome", J Immunol, 172, pp.7661~7668 (2004)
  40. Schwartzentruber DJ, "Guidelines for the safe administration of high-dose interleukin-2", J Immunother, 24, pp.287~293 (2001)
  41. Chen B, "Evaluation of cytokine toxicity induced by vaccinia virus-mediated IL-2 and IL-12 antitumour immunotherapy", Cytokine, 15, pp.305~314 (2001)
  42. Kammula US, "Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer", Cancer, 83, pp.797~805 (1998)
  43. Lotze MT, "Clinical effects and toxicity of interleukin-2 in patients with cancer", Cancer, 58, pp.2764~2772 (1986)
  44. Yang JC, "A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer", N Engl J Med, 349, pp.427~434 (2003)
  45. Mizoguchi H, "Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice", Science, 258, pp.1795~1798 (1992)
  46. Salvadori S, "Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors", J Immunol, 153, pp.5176~5182 (1994)
  47. Fearon ER, "Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response", Cell, 60, pp.397~403 (1990)
  48. Gansbacher B, "Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity", J Exp Med, 172, pp.1217~1224 (1990)
  49. Bannerji R, "The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity", J Immunol, 152, pp.2324~2332 (1994)
  50. Allione A, "Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants", Cancer Res, 54, pp.6022~6026 (1994)
  51. Lollini PL, "Cancer immunoprevention: tracking down persistent tumor antigens", Trends Immunol, 24, pp.62~66 (2003)
  52. Tjuvajev J, "RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma", CancerRes, 55, pp.1902~1910 (1995)
  53. Saparov A, "Interleukin-2 expression by a subpopulation of primary T cells is linked to enhanced memory", effector function, 1999, pp.11, 271~280
  54. Nizard P, "Anchoring cytokines to tumor cells for the preparation of anticancer vaccines without gene transfection in mice", J Immunother, 26, pp.63~71 (2003)
  55. Ji J, "Synergistic anti-tumor effect of glycosylphosphatidylinositol-anchored IL-2 and IL-12", J Gene Med, 6, pp.777~785 (2004)
  56. Ji J, "Glycoinositol phospholipid-anchored interleukin 2 but not secreted interleukin 2 inhibits melanoma tumor growth in mice", Mol Cancer Ther, 1, pp.1019~1024 (2002)
  57. SONN, CHUNG HEE, "MethA Fibrosarcoma Cells Expressing Membrane-Bound Forms of IL-2 Enhance Antitumor Immunity", Journal of Microbiology and Biotechnology, 16(12), pp.1919~1927 (2006), 한국미생물·생명공학회
  58. 장미라, "Antitumor immunity induced by tumor cells engineered to express a membrane-bound form of IL-2", Experimental and Molecular Medicine, 37(3), pp.240~249 (2005), 생화학분자생물학회
  59. 최진화, "Anti-tumor Immunity Induced by Tumor Cells Expressing a Membrane-bound Form of IL-2 and SDF-1", Animal Cells and Systems, 12(4), pp.193~201 (2008), 한국통합생물학회
  60. Tepper RI, "Murine interleukin-4 displays potent anti-tumor activity in vivo", Cell, 57, pp.503~512 (1989)
  61. Huang LR, "Potent induction of long-term CD8＋ T cell memory by short-term IL-4 exposure during T cell receptor stimulation", Proc Natl Acad Sci U S A, 97, pp.3406~3411 (2000)
  62. Schuler T, "Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8(＋)T cells", J Exp Med, 194, pp.1767~1775 (2001)
  63. Schuler T, "T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice", J Exp Med, 189, pp.803~810 (1999)
  64. Song K, "Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer", Gene Ther, 7, pp.481~492 (2000)
  65. Chakrabarti R, "Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen", Vaccine, 22, pp.1199~1205 (2004)
  66. Kim YS, "Tumor cells expressing membrane-bound form of IL-4 induce antitumor immunity", Gene Ther, 7, pp.837~843 (2000)
  67. Herbert AS, "Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge", Virol J, 6, pp.42~ (2009)
  68. Stern AS, "Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells", Proc Natl Acad Sci U S A, 87, pp.6808~6812 (1990)
  69. Kobayashi M, "Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes", J Exp Med, 170, pp.827~845 (1989)
  70. Chan SH, "Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF", IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2, 1992, pp.148, 92~98
  71. Nastala CL, "Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production", J Immunol, 153, pp.1697~1706 (1994)
  72. Hsieh CS, "Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic system", Proc Natl Acad Sci U S A, 89, pp.6065~6069 (1992)
  73. Fan X, "The proinflammatory cytokine interleukin-12 occurs as a cell membrane-bound form on macrophages", Biochem Biophys Res Commun, 225, pp.1063~1067 (1996)
  74. Brunda MJ, "Antitumor and antimetastatic activity of interleukin 12 against murine tumors", J Exp Med, 178, pp.1223~1230 (1993)
  75. Car BD, "The toxicology of interleukin-12: a review", Toxicol Pathol, 27, pp.58~63 (1999)
  76. Atkins MB, "Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies", Clin Cancer Res, 3, pp.409~417 (1997)
  77. Leonard JP, "Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production", Blood, 90, pp.2541~2548 (1997)
  78. Sun Y, "Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study", Gene Ther, 5, pp.481~490 (1998)
  79. Liu Y, "In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma", Cancer Gene Ther, 9, pp.9~15 (2002)
  80. Okada Y, "Optimization of antitumor efficacy and safety of in vivo cytokine gene therapy using RGD fiber-mutant adenovirus vector for preexisting murine melanoma", Biochim Biophys Acta, 1670, pp.172~180 (2004)
  81. Kang WK, "Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study", Hum Gene Ther, 12, pp.671~684 (2001)
  82. Cimino AM, "protein transfer of membrane-anchored cytokines and immunostimulatory molecules", Immunol Res, 29, pp.231~240 (2004)
  83. Nagarajan S, "Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response", Cancer Res, 62, pp.2869~2874 (2002)
  84. Maraskovsky E, "Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified", J Exp Med, 184, pp.1953~1962 (1996)
  85. Shaw SG, "Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy", J Immunol, 161, pp.2817~2824 (1998)
  86. Chen K, "Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model", Cancer Res, 57, pp.3511~3516 (1997)
  87. Alsheikhly AR, "Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following suicide gene therapy in a murine colon carcinoma model", Cancer Immunol Immunother, 53, pp.946~954 (2004)
  88. Wang YC, "Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice", Eur J Immunol, 25, pp.1163~1167 (1995)
  89. Garton KJ, "Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1)", J Biol Chem, 276, pp.37993~38001 (2001)
  90. Zhang X, "Activation of human natural killer cells by recombinant membrane-expressed fractalkine on the surface of tumor cells", Oncol Rep, 17, pp.1371~1375 (2007)
  91. Ren T, "Down-regulation of surface fractalkine by RNA interference in B16 melanoma reduced tumor growth in mice", Biochem Biophys Res Commun, 364, pp.978~984 (2007)
  92. Guo J, "Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells", Int J Cancer, 103, pp.212~220 (2003)
  93. Tang L, "Gene therapy with CX3CL1", Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma, 2007, pp.14, 1226~1234
  94. Vitale S, "Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer", Gut, 56, pp.365~372 (2007)

관련 논문AI추천

Membrane-bound p35 Subunit of IL-12 on Tumor Cells is Functionally Equivalent to Membrane-bound Heterodimeric Single Chain IL-12 for Induction of Anti-tumor Immunity김영상, 김현진, 박상민, 이혜영대한면역학회 · Immune Network2016 · 제16권 제5호Tumor Cell Clone Expressing the Membrane-bound Form of IL-12p35 Subunit Stimulates Antitumor Immune Responses Dominated by CD8＋ T Cells김영상, 도선아, 박상민, 임호영대한면역학회 · Immune Network2013 · 제13권 제2호Ectopically Expressed Membrane-bound Form of IL-9 Exerts Immune-stimulatory Effect on CT26 Colon Carcinoma Cells김영상, 박상민, 이혜영대한면역학회 · Immune Network2018 · 제18권 제1호Cytokine-overexpressing dendritic cells for cancer immunotherapyHan Joonsu, Wang Hua생화학분자생물학회 · Experimental and Molecular Medicine2024 · 제56권 Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy이병하, Dhar Swati, Ezeanya Ugonna I., Ferrando-Martínez Sara, Goon Jack B., Wolfarth Alexandra A.대한면역학회 · Immune Network2022 · 제22권 제1호Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7김지혜, 이건주, Seung-Woo Lee생화학분자생물학회 · BMB Reports2021 · 제54권 제1호

이 간행물의 다른 논문 (6건)

The Prospects of Vitamin C in Cancer Therapy이왕재pp. 147-152Inhibition of Leukocyte Adhesion by Developmental Endothelial Locus-1 (Del-1)Eun Young Choipp. 153-157Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene성영철, 장준, 서유석, 조재호, 진현탁, 최소영pp. 169-178Prophylactic and Therapeutic Potential of Asp f1 Epitopes in Naïve and Sensitized BALB/c MiceGajendra Pratap Singh Raghava, Lakshna Mahajan, Taruna Madan, Seturam Bandacharya Katti, Wahajul Haq, Puranam Usha Sarma, Anil Kumar, Neelkamal Chaudharypp. 179-191Nitric Oxide Synthesis is Modulated by 1,25-Dihydroxyvitamin D3 and Interferon-γ in Human Macrophages after Mycobacterial Infection육재민, 이지숙, 조은경, 양철수, 신동민, 손지웅pp. 192-202
원문 보기